Trial NCT05096832
Publication Xuan-Yi Wang, Emerg Microbes Infec, 2022
Primary outcome on the report: 1) Confirmed symptomatic SARS-CoV- 2 infection with onset at least 14 days after the administration of study-agents, and secondary endpoint was protection of severe or critical COVID-19; 2) Local or systemic adverse events occurred within 28 days after the receipt of study-agent.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.